NCT05256524View on ClinicalTrials.gov

Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?

CompletedOBSERVATIONAL
Enrollment

1,520

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

August 29, 2021

Conditions
Covid19ThromboembolismBleeding
Interventions
DRUG

The effect of LMWH

Quantified by aFXa-levels

DIAGNOSTIC_TEST

Monitoring frequency of aFXa-levels

The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking

Trial Locations (1)

11883

Södersjukhuset, Stockholm

All Listed Sponsors
collaborator

Lund University

OTHER

lead

Karolinska Institutet

OTHER

NCT05256524 - Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin? | Biotech Hunter | Biotech Hunter